| Zhang, Yan |
NCT04790305: Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer |
|
|
| Recruiting | 4 | 1072 | RoW | Huaier Granule, Z20000109（NMPA Approval Number） | Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast | 12/27 | 07/28 | | |
ETER701, NCT04234607: A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 738 | RoW | TQB2450, Anlotinib, Etoposide, Carboplatin, TQB2450（blank）, Anlotinib（blank) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Extensive Small Cell Lung Cancer | 12/22 | 12/22 | | |
| Active, not recruiting | 3 | 453 | Europe, US, RoW | MRTX849, adagrasib, KRAZATI, Docetaxel, Taxotere | Mirati Therapeutics Inc., Mirati Therapeutics, Inc. | Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer | 12/23 | 12/24 | | |
|
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 368 | Europe, US, RoW | SHR0302, Placebo | Reistone Biopharma Company Limited, Reistone Biopharma Company Limited | Ulcerative Colitis | 10/24 | 03/25 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
LEAD, NCT05092412: Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC |
|
|
| Active, not recruiting | 2 | 30 | RoW | Low-dose radiotherapy, Durvalumab, Etoposide, and cisplatin/carboplatin | You Lu, AstraZeneca | Lung Cancer, Extensive-stage Small-cell Lung Cancer, Durvalumab | 02/23 | 06/25 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
FOCUS-C, NCT05334277: Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA |
|
|
| Recruiting | 2 | 280 | RoW | Furmonertinib, AST2818, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab | Sun Yat-sen University, Allist Pharmaceuticals, Inc., GeneCast Biotechnology Co., Ltd. | Non-small Cell Lung Cancer | 02/25 | 02/28 | | |
NCT05867771: A Study of PM1022 in Patients With Advanced Tumors |
|
|
| Recruiting | 1/2 | 200 | RoW | PM1022 | Biotheus Inc. | Advanced Tumors | 04/24 | 04/25 | | |
NCT05416775: Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 168 | RoW | SHR-8068；Adebrelimab, SHR-8068；adebrelimab and platinum-based chemotherapy, Adebrelimab；platinum-based chemotherapy | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Non-small Cell Lung Cancer | 06/26 | 06/26 | | |
NCT05245916: IBI397 or Combination Therapies in Patients With Advanced Malignancies |
|
|
| Withdrawn | 1a/1b | 30 | RoW | IBI397, IBI397+Sintilimab, IBI397+Rituximab | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Malignancies | 08/23 | 08/23 | | |
NCT04487093: Clinical Study of Neoantigen Vaccine Combined With Targeted Drugs in the Treatment of Non-small Cell Lung Cancer |
|
|
| Recruiting | 1 | 20 | RoW | neoantigen vaccine + EGFR-TKI, neoantigen vaccine + anti-angioge | First Hospital of Shijiazhuang City, Tianjin Hengjia Biotechnology Development co., LTD | Non Small Cell Lung Cancer | 05/22 | 12/22 | | |
| Recruiting | 1 | 132 | Japan, RoW | SHR-A2009 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumors | 12/23 | 12/24 | | |
NCT05508334: A Study to Assess the Safety and Tolerability of RC88 for Patients with Advanced Solid Tumours |
|
|
| Active, not recruiting | 1 | 81 | RoW | RC88, The injectable RC88 | RemeGen Co., Ltd. | Advanced Solid Tumours | 06/25 | 12/25 | | |
| Recruiting | 1 | 156 | US, RoW | CS5001 | CStone Pharmaceuticals | Advanced Solid Tumor, Advanced Lymphoma | 03/25 | 06/25 | | |
|
NCT06384352: A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 155 | Canada, US, RoW | YL211 | MediLink Therapeutics (Suzhou) Co., Ltd., Hoffmann-La Roche | Advanced Solid Tumors | 04/27 | 04/29 | | |
UltraFuture I, NCT05498740: Post-marketing Study in Femoral Popliteal Artery of Drug Coated Balloon Used for Treatment of Lower Limb Ischemia |
|
|
| Recruiting | N/A | 200 | RoW | Drug eluting Balloon | Zhejiang Zylox Medical Device Co., Ltd. | Peripheral Arterial Disease (PAD) | 12/22 | 12/24 | | |
DELTA, NCT05608655: DKutting Balloon Versus Chocolate Balloon to Treat Femoral and Popliteal Artery Stenosis |
|
|
| Completed | N/A | 188 | RoW | DKutting LL balloon, Chocolate balloon | DK Medical Technology (Suzhou) Co., Ltd. | Femoral Artery Stenosis, Popliteal Artery Stenosis | 01/24 | 02/24 | | |
| Not yet recruiting | N/A | 768 | RoW | early pancreatic stent placement (EPSP), late pancreatic stent placement (EPSP) | The First Affiliated Hospital of Anhui Medical University, First Affiliated Hospital Bengbu Medical College, Anqing Municipal Hospital, First Affiliated Hospital of Wannan Medical College, Tongcheng People's Hospital of Anhui province, Fuyang people's hospital | Cholangiopancreatography, Endoscopic Rretrograde, Post-ERCP Pancreatitis | 03/26 | 03/26 | | |
| Jia, Jianping |
NCT05908695: An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease |
|
|
| Recruiting | 4 | 1312 | RoW | GV-971, Placebo | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer's Disease | 06/29 | 12/29 | | |
NCT03789760: The Clinical Trial of Chinese Herbal Medicine (SaiLuoTong) Capsule |
|
|
| Completed | 3 | 493 | RoW | SaiLuoTong capsule, The effects of SaiLuoTong capsule on VaD, placebo | Shineway Pharmaceutical Co.,Ltd | Vascular Dementia | 03/24 | 05/24 | | |
NCT03804229: Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia |
|
|
| Active, not recruiting | 3 | 707 | RoW | Butylphthalide soft capsule, The effects of Butylphthalide soft capsule on VaD, Placebo soft capsule, Placebo | Capital Medical University, CSPC-NBP Pharmaceutical Co., Ltd. | Vascular Dementia | 10/24 | 02/25 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
NCT05811442: Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease |
|
|
| Recruiting | 2a | 60 | RoW | 50561 high dose, 50561 low dose, Placebo | Beijing Joekai Biotechnology LLC | Alzheimer's Disease | 05/24 | 06/24 | | |
NCT05269173: Efficacy and Safety of Flos Gossypii Flavonoids Tablet in the Treatment of Alzheimer's Disease |
|
|
| Completed | 2 | 240 | RoW | Flos gossypii flavonoids tablet | Capital Medical University, Xinjiang Uygur Pharmaceutical Co., Ltd. | Alzheimer Disease | 08/24 | 11/24 | | |
| Zhang, Yi |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
NCT04398940: A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 71 | RoW | TQ-B3139 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 01/22 | 10/22 | | |
NCT03638206: Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies |
|
|
| Recruiting | 1/2 | 73 | RoW | CAR-T cell immunotherapy | Shenzhen BinDeBio Ltd., The First Affiliated Hospital of Zhengzhou University | B-cell Acute Lymphoblastic Leukemia, Lymphoma, Myeloid Leukemia, Multiple Myeloma, Hepatoma, Gastric Cancer, Pancreatic Cancer, Mesothelioma, Colorectal Cancer, Esophagus Cancer, Lung Cancer, Glioma, Melanoma, Synovial Sarcoma, Ovarian Cancer, Renal Carcinoma | 03/23 | 03/23 | | |
NCT05117138: Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors |
|
|
| Not yet recruiting | 1/2 | 39 | RoW | AMT-116 CAR-T cells, AMT-253 CAR-T cells | Beijing Immunochina Medical Science & Technology Co., Ltd. | Melanoma, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | 12/23 | 03/24 | | |
NCT06316791: Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases |
|
|
| Recruiting | 1 | 24 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Lupus Erythematosus, Systemic | 12/24 | 12/25 | | |
NCT05122221: CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers |
|
|
| Recruiting | 1 | 12 | RoW | Fludarabine + Cyclophosphamide, Interleukin-2, CRTE7A2-01 TCR-T Cell | Corregene Biotechnology Co., Ltd | Cervical Cancer, Anal Cancer, Head and Neck Cancers | 03/23 | 12/24 | | |
NCT06152757: BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors |
|
|
| Recruiting | 1 | 14 | RoW | First dose, Second dose, The third dose, The fourth dose | BioSyngen Pte Ltd, The First Affiliated Hospital of Zhengzhou University | Gastrointestinal Tumors | 07/25 | 07/27 | | |
NCT05381181: Safety and Efficacy Evaluation of Next-generation CD19-UCART |
|
|
| Not yet recruiting | 1 | 20 | NA | CD19-UCART | Bioray Laboratories, The First Affiliated Hospital of Zhengzhou University | Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma | 05/24 | 05/26 | | |
NCT06077903: GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors |
|
|
| Recruiting | 1 | 20 | RoW | GT101 | Grit Biotechnology | Adult | 07/24 | 07/24 | | |
NCT06548620: A Study of RD06-04 in Patients With Active Autoimmune Diseases |
|
|
| Not yet recruiting | 1 | 18 | RoW | RD06-04 cell infusion | Nanjing Bioheng Biotech Co., Ltd. | SLE (Systemic Lupus), Sclerosis, ANCA Associated Vasculitis, IIM, SS, MS, NMO Spectrum Disorder, MG | 08/26 | 08/27 | | |
NCT06094426: Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | GT316 | Grit Biotechnology | Solid Tumor, Adult, GT316 | 02/26 | 02/26 | | |
NCT03908671: Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 24 | RoW | Personalized mRNA Tumor Vaccine | Stemirna Therapeutics, The First Affiliated Hospital of Zhengzhou University | Esophageal Cancer, Non Small Cell Lung Cancer | 10/24 | 12/25 | | |
NCT06658951: Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors |
|
|
| Not yet recruiting | N/A | 30 | RoW | Anti-HER2 CAR-T cells | UTC Therapeutics Inc., The First Affiliated Hospital of Zhengzhou University | HER2-positive Advanced Malignant Solid Tumors | 11/26 | 11/27 | | |
NCT05308875: Efficacy and Safety Evaluation of PD1-BCMA-CART |
|
|
| Not yet recruiting | N/A | 9 | RoW | PD1-BCMA-CART | Bioray Laboratories, The First Affiliated Hospital of Zhengzhou University | Multiple Myeloma | 01/25 | 10/25 | | |
| Recruiting | N/A | 1000 | US | MicroVention Mechanical Thrombectomy Devices as first-line treatment | Microvention-Terumo, Inc. | Acute Ischemic Stroke, Vessel Occlusion, Stroke, Ischemic | 12/25 | 12/25 | | |
NCT05409989: MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study |
|
|
| Recruiting | N/A | 154 | US | FRED™ X™, Flow Re-Direction Endoluminal Device X | Microvention-Terumo, Inc. | Intracranial Aneurysm | 09/29 | 11/29 | | |
| Su, Li |
NCT04324879: A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL) |
|
|
| Recruiting | 2 | 80 | RoW | TQ-B3525 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Relapsed / Refractory Follicular Lymphoma | 12/22 | 12/22 | | |
UltraFuture I, NCT05498740: Post-marketing Study in Femoral Popliteal Artery of Drug Coated Balloon Used for Treatment of Lower Limb Ischemia |
|
|
| Recruiting | N/A | 200 | RoW | Drug eluting Balloon | Zhejiang Zylox Medical Device Co., Ltd. | Peripheral Arterial Disease (PAD) | 12/22 | 12/24 | | |
| Hua, Qi |
| Completed | 2 | 225 | RoW | Qishen Yiqi dripping pills 2 bags/time + Qishen Yiqi dripping pills placebo 2 bags/time, Qishen Yiqi dripping pills 4 bags/time, Qishen Yiqi dripping pills placebo 4 bags/time | Tasly Pharmaceutical Group Co., Ltd | Chronic Heart Failure With Preserved Ejection Fraction | 12/24 | 12/24 | | |
| Hao, Junwei |
OPTION, NCT05752916: Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window |
|
|
| Recruiting | 4 | 568 | RoW | rhTNK-tPA, Antiplatelet Agents, Aspirin, Clopidogrel | Xuanwu Hospital, Beijing, Guangzhou Recomgen Biotech Co., Ltd. | Acute Ischemic Stroke | 12/25 | 12/25 | | |
NCT06485232: Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System. |
|
|
| Not yet recruiting | 1 | 25 | RoW | Universal BCMA CAR-T, Universal CD19 CAR-T, Universal BCMA CAR-T; Universal CD19 CAR-T | Xuanwu Hospital, Beijing, Bioray Laboratories | Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Generalized, Multiple Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy | 12/26 | 12/27 | | |
| Guo, Lianrui |
DELTA, NCT05608655: DKutting Balloon Versus Chocolate Balloon to Treat Femoral and Popliteal Artery Stenosis |
|
|
| Completed | N/A | 188 | RoW | DKutting LL balloon, Chocolate balloon | DK Medical Technology (Suzhou) Co., Ltd. | Femoral Artery Stenosis, Popliteal Artery Stenosis | 01/24 | 02/24 | | |
PINTO, NCT05562076: Clinical Study of Focal Implant Used for Lower Extremity Post-angioplasty Dissection |
|
|
| Not yet recruiting | N/A | 224 | RoW | the spot stent(ZENFLEX ® Pinto) system, the bare stent( Everflex) system | Zhejiang Zylox Medical Device Co., Ltd. | Peripheral Artery Disease | 02/24 | 02/25 | | |
GENIUS, NCT04849325: IBS Titan vs. PTA in Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease |
|
|
| Recruiting | N/A | 120 | RoW | Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titanâ„¢), Percutaneous Transluminal Angioplasty (PTA) Device | Biotyx Medical (Shenzhen) Co., Ltd. | Critical Limb Ischemia (CLI) | 04/24 | 10/24 | | |
| Wang, Yuping |
NCT06010693: A Study of Daridorexant in Chinese Patients With Insomnia Disorder |
|
|
| Completed | 3 | 206 | RoW | Daridorexant, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Insomnia Disorder | 04/24 | 05/24 | | |
NCT06279286: Phase Ⅰb/Ⅱ Study of HS-10506 in Chinese Participants With Insomnia Disorder |
|
|
| Not yet recruiting | 1/2 | 312 | RoW | HS-10506, Placebo | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Insomnia Disorder | 01/25 | 01/25 | | |
| Ma, Qingfeng |
OPTION, NCT05752916: Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window |
|
|
| Recruiting | 4 | 568 | RoW | rhTNK-tPA, Antiplatelet Agents, Aspirin, Clopidogrel | Xuanwu Hospital, Beijing, Guangzhou Recomgen Biotech Co., Ltd. | Acute Ischemic Stroke | 12/25 | 12/25 | | |
| Completed | 3 | 1412 | RoW | Injection of recombinant human tissue plasminogen kinase derivatives, Reteplase, brand name: Ruitongli, r-PA, Recombinant human tissue plasminogen activator, Alteplase, brand name: Actilyse, rt-PA | Angde Biotech Pharmaceutical Co., Ltd., Beijing Tiantan Hospital | Acute Ischemic Stroke | 06/23 | 06/23 | | |
| Li, Kaifu |
| No trials found |
| Yuan, Shuhua |
| No trials found |
| Zhou, Aihong |
| No trials found |
